Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

NCT07412041 | Not Yet Recruiting

• 1 other identifier: 25-607
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

Conditions

Stage II Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer; NSCLC

Keywords

Stage II Lung Cancer; Lung Cancer; Non-small Cell Lung Cancer; NSCLC

Outcome Measures

Primary Outcomes (1)

• Attendance of Exercise Sessions (Feasibility)

  Defined as the proportion of enrolled participants who complete ≥80% of the prescribed exercise sessions.

  From first exercise session to final exercise session (up to 24 weeks)

Other Outcomes (16)

• Treatment Delays

  Defined as time between neoadjuvant therapy and surgery

• Physical Function (Short Physical Performance Battery - SPPB)

  From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

• Quality of Life (Functional Assessment of Cancer Therapy - Lung [FACT-L])

  From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

Study Arms (1)

PERCC

EXPERIMENTAL

Receives personalized virtual exercise program (aerobic and resistance exercise) 1x weekly for patients with lung cancer who plan on receiving neoadjuvant treatment followed by surgery.

Behavioral: PERCC

Interventions

PERCC BEHAVIORAL

Personalized at-home exercise program, including aerobic and resistance exercise. Supervised by trained exercise professional via ZOOM (HIPPA complaint video conferencing platform). Study equipment of Fitbit and resistance bands will be provided to participants.

Also known as: Precise Exercise Regimen for Cancer Care (PERCC)

PERCC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years at time of diagnosis; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
• Histologically diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.
• Patient's treatment plan is to receive neoadjuvant therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.
• Ability to follow directions and complete questionnaires in English and/or Spanish.
• Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.
• Willing to travel to DFCI for necessary data collection.

You may not qualify if:

• Patients who are morbidly obese (BMI\>40 kg/m2) or Anorexic (BMI\<17 kg/m2).
• Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.
• Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).
• Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.
• Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
• Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

Sponsors & Collaborators

• Dana-Farber Cancer Institute: lead

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Christina Dieli-Conwright, PhD, MPH

  Dana-Farber Cancer Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Christina Dieli-Conwright, PhD, MPH

CONTACT

617-582-8321; christinam_dieli-conwright@dfci.harvard.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 2, 2026
• First Posted: February 17, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): September 30, 2027
• Study Completion (Estimated): September 30, 2028
• Last Updated: February 17, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Data can be shared no earlier than 1 year following the date of publication
• Access Criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu